comprehensive -WSS

comprehensive

author：entertainment 2025-10-02 18:48:15 - browse：39

Neumora, a privately held biotech company, is moving into the final phase of testing with a novel treatment for depression that showed promise in a mid-stage trial.

The drug, a daily pill called navacaprant, led to statistically significant improvements over placebo on a measurement of disease severity for patients with moderate to severe major depressive disorder, Neumora said Tuesday. In the eight-week study, the medicine also led to improvements in patient-reported anhedonia, a reduced ability to experience pleasure that often accompanies severe depression.

Navacaprant’s statistically significant benefits came from a pre-specified subset of 100 patients in a study that enrolled 171 people. In the total population, including 71 patients who had mild to moderate disease, navacaprant’s effect on depressive symptoms was numerically superior to placebo but did not reach the threshold of statistical significance, missing the study’s primary endpoint.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Eye stem cell transplant could help restore vision in injured people

focus

WSS

Faced with fears of OxyContin misuse, sales reps touted its safety

Who are the detained American citizens released from prison in Iran?

GOP presidential candidates start declaring their loyalty

Hilary may become 1st tropical storm to make landfall in California in 84 years

Eye stem cell transplant could help restore vision in injured people

Beware the threat of staffing cuts at the CDC

Wikipedia

comprehensive

Wikipedia

United colonoscopy coverage change 'may cost lives,' doctors say

The history of OxyContin, told through Purdue Pharma documents

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Cancer drug shortages' outsize impact on ovarian cancer patients

Peter Hotez and the public health issue of online harassment

Patient advocates sound warning on FDA proposal on salt intake

Moonlake's readout produced a cash windfall. Risks remain

Listen: Your guide to Wegovy's blockbuster heart study

Wildfire smoke exposes gaps in outdoor worker protections

Genentech weighs delaying cancer therapy after drug pricing law

leisure time

Beware the threat of staffing cuts at the CDC

Pharma budget tightening trickles down to Doximity

The boys, now 6, who are gene therapy’s ‘edge case’ problem

Timeline: Special counsel's investigation into Trump's handling of classified documents

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

Large hospital system sues Multiplan for low

focus

hotspot

focus

hotspot